BAM
LEXX icon

Byrne Asset Management’s Lexaria Bioscience LEXX Stock Holding History

Byrne Asset Management’s Portfolio LEXX Stock Details LEXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-53
Closed -$624 – 606
2026
Q1 		$624 Sell
53
-6,980
-99% -$76K ﹤0.01% 546
2025
Q4 		$65.1K Buy
7,033
+4,945
+237% +$70.2K 0.04% 258
2025
Q3 		$29.8K Sell
2,088
-193
-8% -$2.8K 0.02% 302
2025
Q2 		$29.8K Buy
2,281
+354
+18% +$6.1K 0.02% 301
2025
Q1 		$49.4K Buy
1,927
+1,060
+122% +$27K 0.04% 210
2024
Q4 		$27.3K Buy
867
+494
+132% +$18.2K 0.02% 251
2024
Q3 		$17.1K Buy
+373
New +$17.8K 0.01% 323

Other funds holding LEXX

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KF
Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Byrne Asset Management's LEXX Position: Q2 2026 in Review

Byrne Asset Management sold out of Lexaria Bioscience (LEXX) in Q2 2026, closing a stake of 53 shares — an estimated $624 sold.

Byrne Asset Management first reported a position in LEXX in Q3 2024 and held it in 7 quarters. The position peaked at $65.1K in Q4 2025. 6 funds tracked by Wall St. Rank hold LEXX as of Q2 2026.

  • Byrne Asset Management reported no remaining Lexaria Bioscience position as of Q2 2026 after selling out during the quarter.
  • Byrne Asset Management sold 53 Lexaria Bioscience shares in Q2 2026, an estimated $624.
  • Byrne Asset Management first reported a position in Lexaria Bioscience in Q3 2024 and held it in 7 quarters.
  • Byrne Asset Management's Lexaria Bioscience position peaked at $65.1K in Q4 2025.
  • 6 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q2 2026.

Based on Byrne Asset Management's 13F filing for Q2 2026, filed 7 Jul 2026.